This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor
cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach
cancer) or non-small cell lung cancer. EF5 may be effective in measuring oxygen in tumor
tissue. Photosensitizing drugs such as motexafin lutetium are absorbed by tumor cells and,
when exposed to light, become active and kill the tumor cells. Knowing the level of oxygen
in tumor tissue and the level of motexafin lutetium absorbed by tumors and normal tissue may
help predict the effectiveness of anticancer therapy
I. Determine the uptake of motexafin lutetium in tumors and normal tissue of patients with
intra-abdominal malignancies or non-small cell lung cancer.
II. Determine the ratio of tumor to normal tissue by measuring the level of motexafin
lutetium uptake in tumor and normal tissue removed from these patients.
III. Determine the pattern, presence, and level of EF5 binding (as a surrogate marker for
hypoxia) in tumors of these patients.
IV. Determine the feasibility of measuring optical properties, tissue oxygenation, motexafin
lutetium concentration, fluorescence, and blood flow by non-invasive means in these
OUTLINE: This is a multicenter, diagnostic study. Patients are stratified according to
diagnosis (intra-abdominal malignancy vs non-small cell lung cancer).
Patients receive EF5 IV over 1-2.5 hours on day 1 and motexafin lutetium IV over 10-15
minutes on day 2. Patients undergo definitive surgical resection approximately 3 hours after
motexafin lutetium administration. Hypoxia and motexafin lutetium levels in the resected
tumors are evaluated. Tumor to normal tissue ratios are also determined.
After completion of study treatment, patients are followed at approximately 1-8 weeks.
PROJECTED ACCRUAL: A total of 30 patients (20 with intra-abdominal malignancies and 10 with
non-small cell lung cancer) will be accrued for this study within 10-15 months.
- Histologically confirmed or suspected diagnosis of 1 of the following:
- Intra-abdominal malignancy of 1 of the following types:
- Ovarian cancer
- Gastrointestinal malignancies, including, but not limited to, appendiceal
cancer, colon cancer, or gastric cancer
- Non-small cell lung cancer
- Planning to undergo surgical resection of disease
- Disease has the propensity to spread to the peritoneal cavity (intra-abdominal
- Performance status - ECOG 0-2
- WBC ≥ 2,000/mm^3
- Platelet count ≥ 100,000/mm^3
- Bilirubin < 1.5 mg/dL
- Creatinine normal
- Creatinine clearance ≥ 60 mL/min
- Body weight ≤ 130 kg
- No G6PD deficiency
- No porphyria
- No history of peripheral neuropathy ≥ grade 3
- Able to tolerate anesthesia and major surgery
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 1 month after study